A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1, 3, 8, 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis